Key facts
- It has raised $153.0M; the latest was Later Stage VC ($53.0M) in Dec 2025.
- Notable investors include Sequoia Capital, Hongshan Capital Group, General Atlantic, ARCH Venture Partners, Boyu Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for SciNeuro Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for SciNeuro Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SciNeuro Pharmaceuticals
Developer of new drugs designed to transform the treatment of CNS diseases with a dedication that begins and ends with patients. The company's drugs have a strong CNS product pipeline through internal innovation and global cooperation and focus on targets supported by evidence from breakthrough science including both human genetics and pharmacology, while addressing the pathological mechanism to achieve the intended treatment benefit, enabling patients suffering from CNS diseases to receive transformative drug therapies to cure their disease and improve their quality of life.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2020
- Employees
- 29
- Website
- scineuro.com/
- Ownership
- Privately Held (backing)
SciNeuro Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SciNeuro Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SciNeuro Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.